Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S.

J Clin Oncol. 2010 Jul 10;28(20):3219-26. doi: 10.1200/JCO.2009.27.1825. Epub 2010 May 24. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664.

PMID:
20498393
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.

J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added].

PMID:
21597022
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M.

J Clin Oncol. 2009 Apr 10;27(11):1814-21. doi: 10.1200/JCO.2008.18.2071. Epub 2009 Mar 9.

PMID:
19273709
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.

J Clin Oncol. 2013 Oct 10;31(29):3664-72. doi: 10.1200/JCO.2013.48.9591. Epub 2013 Sep 9.

PMID:
24019539
[PubMed - indexed for MEDLINE]
5.

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.

Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.

Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67. doi: 10.1007/s00280-009-1206-3. Epub 2009 Dec 24.

PMID:
20033812
[PubMed - indexed for MEDLINE]
6.

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.

Li P, Fang YJ, Li F, Ou QJ, Chen G, Ma G.

Br J Cancer. 2013 Apr 2;108(6):1238-44. doi: 10.1038/bjc.2013.83. Epub 2013 Mar 12.

PMID:
23481186
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.

Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.

Clin Cancer Res. 2011 Dec 1;17(23):7470-8. doi: 10.1158/1078-0432.CCR-11-1048. Epub 2011 Oct 13.

PMID:
21998335
[PubMed - indexed for MEDLINE]
Free Article
8.

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G.

BMC Gastroenterol. 2013 Feb 27;13:36. doi: 10.1186/1471-230X-13-36.

PMID:
23446022
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.

Öhrling K, Karlberg M, Edler D, Hallström M, Ragnhammar P.

Clin Colorectal Cancer. 2013 Jun;12(2):128-35. doi: 10.1016/j.clcc.2012.11.003. Epub 2012 Dec 29.

PMID:
23276521
[PubMed - indexed for MEDLINE]
10.

Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.

Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ.

J Clin Oncol. 2012 Feb 1;30(4):406-12. doi: 10.1200/JCO.2011.39.2563. Epub 2011 Dec 27.

PMID:
22203756
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN.

Clin Cancer Res. 2008 Jun 1;14(11):3408-15. doi: 10.1158/1078-0432.CCR-07-1489.

PMID:
18519771
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.

Kim JE, Hong YS, Ryu MH, Lee JL, Chang HM, Lim SB, Kim JH, Jang SJ, Kim MJ, Yu CS, Kang YK, Kim JC, Kim TW.

Cancer Sci. 2011 Sep;102(9):1706-11. doi: 10.1111/j.1349-7006.2011.02009.x. Epub 2011 Jul 12.

PMID:
21679278
[PubMed - indexed for MEDLINE]
13.

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N.

J Clin Oncol. 2013 Dec 20;31(36):4512-9. doi: 10.1200/JCO.2012.47.3116. Epub 2013 Nov 12. Erratum in: J Clin Oncol. 2014 Mar 10;32(8):866.

PMID:
24220557
[PubMed - indexed for MEDLINE]
14.

Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.

Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS.

J Clin Oncol. 2005 Mar 20;23(9):1819-25.

PMID:
15774775
[PubMed - indexed for MEDLINE]
Free Article
15.

Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.

Scheithauer W, Kornek GV, Marczell A, Karner J, Salem G, Greiner R, Burger D, Stöger F, Ritschel J, Kovats E, Vischer HM, Schneeweiss B, Depisch D.

Br J Cancer. 1998 Apr;77(8):1349-54.

PMID:
9579845
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.

Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N.

Ann Surg Oncol. 2010 Apr;17(4):959-66. doi: 10.1245/s10434-009-0881-y.

PMID:
20082144
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1797-806. Epub 2004 Apr 5.

PMID:
15067028
[PubMed - indexed for MEDLINE]
Free Article
18.

Thymidylate synthase expression in colon carcinomas with microsatellite instability.

Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, La Plant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, Witzig TE, Thibodeau SN.

Clin Cancer Res. 2006 May 1;12(9):2738-44.

PMID:
16675565
[PubMed - indexed for MEDLINE]
Free Article
19.

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS.

Clin Cancer Res. 2012 Feb 1;18(3):890-900. doi: 10.1158/1078-0432.CCR-11-2246. Epub 2011 Dec 6.

PMID:
22147942
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.

Ohrling K, Edler D, Hallström M, Ragnhammar P.

Acta Oncol. 2010 Aug;49(6):797-804. doi: 10.3109/02841861003705786.

PMID:
20307245
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk